Sulphanilamide in Erysipelas

Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases

“…Early antibiotic trials focused on patients with life-threatening infections and the outcome of all-cause survival [12]. While investigators demonstrated interest in evaluating "patient toxicity" (referring to symptoms/function) in survivors, no tools existed at the time to do so [13,14]. Even in some potentially life-threatening diseases, mortality rates remain proportionally low.…”

The Chemotherapy of Sulphon-Amides

“…Proseptasine has the advantage that an accidental overdosage would not cause serious symptoms as in the case of sulphanilamide; also the toxic symptoms are less than those of equivalent quantities of the former drug. In a report 6 where a comparison of the drugs was attempted in erysipelas, Proseptasine has proved definitely but slightly less active than sulphanilamide. The two soluble compounds at present in general use, Prontosil Soluble and Soluseptasine, both belong to this class of substances.…”

TheBritish Journal of Dermatology: the interwar years

“…A regular feature of the BJD&S during this era was the Survey of Dermatological Literature. References in this section from 1938 included reports from the British Medical Journal and The Lancet on the treatment of erysipelas with sulfamidochrysoidine, sulfanilamide and benzyl sulfanilamide, and the treatment of infected wounds with urine . These reports were clearly intended to help dermatologists by identifying important research published in other journals, which might otherwise have eluded them; they now serve to highlight therapeutic impotence for dermatologists in the face of intractable clinical problems.…”